Key clinical point: Overall survival among men with castration sensitive prostate cancer was similar whether they were treated with docetaxel or abiraterone, but progression-free survival favored abiraterone patients.
Major finding: Progression-free survival at 12 months was greater among men who received ABI compared to those who received DOC (79.7% vs. 67.1%). Overall survival rates at 12 months were similar between the ABI and DOC groups (92.7% and 98.7%, respectively).
Study details: The data come from a retrospective analysis of 121 men with castration sensitive prostate cancer (mCSPC) who were treated at a single center between December 2014 and March 2021; 79 received docetaxel and 42 received abiraterone in addition to androgen deprivation therapy.
Disclosures: The study was supported by the Joseph and Silvana Melara Cancer Research Fund. Lead author Dr. Briones had no financial conflicts to disclose.
Source: Briones J et al. Front Oncol. 2021 May 7. doi: 10.3389/fonc.2021.658331.